Idelalisib: First-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma

Clinical Cancer Research

Volumn 21, Issue 7, 2015, Pages 1537-1542

  Yang, Qingshan ^a   Modi, Prexy ^a   Newcomb, Terry ^b   Quéva, Christophe ^b   Gandhi, Varsha ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Gilead Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 319; ANTINEOPLASTIC AGENT; BREAKPOINT CLUSTER REGION PROTEIN; BRENTUXIMAB VEDOTIN; BRUTON TYROSINE KINASE INHIBITOR; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CHLORAMBUCIL; DUVELISIB; FC RECEPTOR; IDELALISIB; INCB 40093; JANUS KINASE 1 INHIBITOR; JANUS KINASE INHIBITOR; OBINUTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 4 PHOSPHATE 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PLACEBO; RITUXIMAB; TGR 1202; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; PIK3CD PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CHILL; CHRONIC LYMPHATIC LEUKEMIA; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSPNEA; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; HYPERTRANSAMINASEMIA; INFUSION RELATED REACTION; INTRACELLULAR SIGNALING; LEUKEMOGENESIS; LYMPHOCYTOMA; MAXIMUM PLASMA CONCENTRATION; MOLECULAR PATHOLOGY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SURVIVAL RATE; SURVIVAL TIME; ANTAGONISTS AND INHIBITORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR;

ANTINEOPLASTIC AGENTS; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR; PROTEIN KINASE INHIBITORS; PURINES; QUINAZOLINONES;

EID: 84927638285     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2034     Document Type: Article

References (46)

1. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014;13:140-56.
2. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116:2078-88.
3. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118:3603-12.
4. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-83.
5. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010;11:329-41.
6. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, et al. Synthesis and function of 3-phosphorylated inositol lipids. Ann Rev Biochem 2001;70:535-602.
7. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2013;110:1398-403.
8. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 2005;30:194-204.
9. Puri KD, Gold MR. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Front Immunol 2012;3:256.
10. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ, et al. P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A 1997;94:4330-5.
11. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002;297:1031-4.
12. Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, Gray A, et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 2002;196:753-63.
13. Jou ST, Carpino N, Takahashi Y, Piekorz R, Chao JR, Wang D, et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 2002;22:8580-91.
14. Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat Immunol 2014;15:88-97.
15. Angulo I, Vadas O, Garcon F, Banham-Hall E, Plagnol V, Leahy TR, et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science 2013;342:866-71.
16. Ali K, Soond DR, Pineiro R, Hagemann T, Pearce W, Lim EL, et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 2014;510:407-11.
17. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591-4.
18. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008;111:846-55.
19. Meadows SA, Vega F, Kashishian A, Johnson D, Diehl V, Miller LL, et al. PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 2012;119:1897-900.
20. Dal Col J, Zancai P, Terrin L, Guidoboni M, Ponzoni M, Pavan A, et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 2008;111:5142-51.
21. Iyengar S, Clear A, Bodor C, Maharaj L, Lee A, Calaminici M, et al. P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood 2013;121:2274-84.
22. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 2003;3:317-30.
23. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88-92.
24. Rodriguez A, Villuendas R, Yanez L, Gomez ME, Diaz R, Pollan M, et al. Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. Leukemia 2007;21:1984-91.
25. Rickert RC. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol 2013;13:578-91.
26. Castello A, Gaya M, Tucholski J, Oellerich T, Lu KH, Tafuri A, et al. Nck-mediated recruitment of BCAP to the BCR regulates the PI(3)K-Akt pathway in B cells. Nat Immunol 2013;14:966-75.
27. Aiba Y, Kameyama M, Yamazaki T, Tedder TF, Kurosaki T. Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase. Blood 2008;111:1497-503.
28. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005;5:921-9.
29. Chantry D, Vojtek A, Kashishian A, Holtzman DA, Wood C, Gray PW, et al. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 1997;272:19236-41.
30. Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J Immunol 2003;170:2647-54.
31. Berndt A, Miller S, Williams O, Le DD, Houseman BT, Pacold JI, et al. The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol 2010;6:117-24.
32. Yang Q, Modi P, Ramanathan S, Queva C, Gandhi V. Idelalisib for the treatment of B-cellmalignancies. Expert Opin Orphan Drugs 2015;3:109-23.
33. Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014;123:3390-7.
34. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370:997-1007.
35. Herman SE, Lapalombella R, Gordon AL, Ramanunni A, Blum KA, Jones J, et al. The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood 2011;117:4323-7.
36. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-69.
37. Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014;123:3406-13.
38. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370:1008-18.
39. Lanasa MC, Glenn M, Mato AR, Allgood SD, Wong S, Amore B, et al. First-in-human study of AMG 319, a highly selective, small molecule inhibitor of PI3Kδ, in adult patients with relapsed or refractory lymphoid malignancies [abstract]. In: Proceedings of the 55th ASH Annual Meeting and Exposition; 2013 Dec 7-10; New Orleans, LA: American Society of Hematology; 2013. Abstract nr 678.
40. O'Brien S, Patel M, Kahl B, Horwitz SM, Foss FM, Porcu P, et al. Duvelisib (IPI-145), a PI3K-δ,γ inhibitor, is clinically active in patients with relapsed/refractory chronic lymphocytic leukemia [abstract]. In: Proceedings of the 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, CA: American Society of Hematology; 2014. Abstract nr 3334.
41. Flinn I, Oki Y, Patel M, Horwitz SM, Foss FM, Sweeney J, et al. A phase 1 evaluation of duvelisib (IPI-145), a PI3K-δ,γ inhibitor, in patients with relapsed/refractory iNHL [abstract]. In: Proceedings of the 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, CA: American Society of Hematology; 2014. Abstract nr 802.
42. Dong S, Guinn D, Dubovsky JA, Zhong Y, Lehman A, Kutok J, et al. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood 2014;124:3583-6.
43. Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda W, et al. Inhibition of PI3K-δ and -γ isoforms by IPI-145 in chronic lymphocytic leukemia overcomes signals from PI3K/AKT/S6 pathway and promotes apoptosis [abstract]. In: Proceedings of the 55th ASH Annual Meeting and Exposition; 2013 Dec 7-10; New Orleans, LA: American Society of Hematology; 2013. Abstract nr 4167.
44. Horwitz SM, Porcu P, Flinn I, Kahl B, Sweeney J, Stern HM, et al. Duvelisib (IPI-145), a phosphoinositide-3-kinase-δ,γ inhibitor, shows activity in patients with relapsed/refractory T-cell lymphoma [abstract]. In: Proceedings of the 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, CA: American Society of Hematology; 2014. Abstract nr 803.
45. Yang Q, Chen LS, Neelapu SS, Gandhi V. The PI3Kδ inhibitor, idelalisib, inhibits transcription and translation through PI3K/Akt pathway in mantle cell lymphoma [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA: AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4529.
46. de Vos S, Wagner-Johnston ND, Coutre SE, Flinn I, Schreeder MT, Fowler NH, et al. Durable responses following treatment with the PI3K-delta inhibitor idelalisib in combination with rituximab, bendamustine, or both, in recurrent indolent non-Hodgkin lymphoma: phase I/II results [abstract]. In: Proceedings of the 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, CA: American Society of Hematology; 2014. Abstract nr 3063.